
- /
- Supported exchanges
- / US
- / NRXPW.NASDAQ
NRx Pharmaceuticals Inc (NRXPW NASDAQ) stock market data APIs
NRx Pharmaceuticals Inc Financial Data Overview
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get NRx Pharmaceuticals Inc data using free add-ons & libraries
Get NRx Pharmaceuticals Inc Fundamental Data
NRx Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -14 127 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NRx Pharmaceuticals Inc News

NRx Pharmaceuticals outlines expanded fast track for NRX-100 and targets $750M ketamine market following balance sheet strengthening
Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q2 2025 MANAGEMENT VIEW * Jonathan C. Javitt, Co-Founder, Chief Scientist Officer, Chairman & Interim CEO, highlighted that NRx Pharmaceuticals i...


New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team
Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the nat...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and its subsidiary, HOPE Therapeutics, Inc., are making a major move in mental health care with the acquisition of Kadima Neuropsychiatry Institute in La Jolla,...

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (" Relief "), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (" NR...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.